

Update: January 21, 2022, added 0073A, updated 91305, 0051A, 0052A, 0053A from pending FDA approval to be retroactive to 10/29/21

Below is the original notice with updates noted in **red** font.

January 12, 2021

Dear Provider:

When billing for administration of the COVID-19 vaccine, the appropriate code for the vaccine itself must also be reported on the claim. The applicable vaccine code must be reported with **no modifier** (DO NOT bill a modifier -SL) and a zero charge, or if your system is not capable of a zero charge, \$0.01 can be billed.


Code	Effective Date	Description
91300	12/11/20	Pfizer- BioNTech vaccine
91301	12/18/20	Moderna vaccine
91302	Pending FDA Approval	AstraZeneca vaccine
91303	02/27/21	Janssen (Johnson & Johnson) vaccine
91305	10/29/21	Pfizer-BioNTech COVID-19 Vaccine (Ready to Use)
91306	10/20/21	Moderna COVID-19 Vaccine (Low Dose)
91307	10/29/21	Pfizer – BioNTech COVID-19 Vaccine (Pediatric)
0001A	12/11/20	Pfizer- BioNTech administration first dose
0002A	12/11/20	Pfizer- BioNTech administration second dose
0003A	8/12/21	Pfizer- BioNTech administration third dose
0004A	09/22/21	Pfizer- BioNTech administration booster
0011A	12/18/20	Moderna administration first dose
0012A	12/18/20	Moderna administration second dose
0013A	08/12/21	Moderna administration third dose
0021A	Pending FDA Approval	AstraZeneca administration first dose
0022A	Pending FDA Approval	AstraZeneca administration second dose
0031A	02/27/21	Janssen (Johnson & Johnson) administration
0034A	10/20/21	Janssen (Johnson & Johnson) administration booster
0051A	10/29/21	Pfizer- BioNTech (Ready to Use) administration first dose
0052A	10/29/21	Pfizer- BioNTech (Ready to Use) administration second dose
0053A	10/29/21	Pfizer- BioNTech (Ready to Use) administration third dose
0054A	Pending FDA Approval	Pfizer-BioNTech (Ready to Use) administration booster
0064A	10/20/21	Moderna (Low Dose) administration booster
0071A	10/29/21	Pfizer- BioNTech administration first dose (Pediatric)
0072A	10/29/21	Pfizer- BioNTech administration second dose (Pediatric)
0073A	01/01/22	Pfizer BioNTech Administration third dose (Pediatric)

The administration will be considered for benefits without member liabilities. The vaccine is not eligible for reimbursement as it is being supplied by the federal government.

Reminder: COVID-19 administration and vaccines for Medicare Advantage members (this includes Vermont Blue Advantage members) need to be billed to the original fee-for-service Medicare Program.

If you have any questions regarding this notice, please feel free to contact your provider relations consultant via email at providerrelations@bcbsvt.com or by phone at (888) 449-0443 option 1. Business hours are Monday through Friday from 8 a.m. to 4:30 p.m., except holidays.

Sincerely,

A handwritten signature in black ink that reads "Lou McLaren". The signature is written in a cursive, slightly slanted style.

Lou McLaren
Director, Provider Services